Triple Negative Breast Cancer (TNBC) Archives - Page 4 of 4

Merck’s Keytruda Hits Another Endpoint, This Time in Triple-Negative Breast Cancer

Analysis, Blockbusters, Checkpoint Inhibitors, Chemotherapy, PD-L1 Inhibitor, Triple Negative Breast Cancer (TNBC)

Merck’s checkpoint inhibitor Keytruda (pembrolizumab) in combination with chemotherapy hit the primary endpoint in the company’s Phase III KEYNOTE-522 in triple-negative breast cancer.

FDA approves Roche’s small cell lung cancer treatment

Approvals, Blockbusters, Extensive-Stage Small Cell Lung Cancer, FDA, FDA/Regulatory, Immune System, Immunotherapies, New Indications, Priority Review, Small cell lung cancer, Triple Negative Breast Cancer (TNBC)

Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.

Anti-PD-L1 Immunotherapy Plus Abraxane Significantly Reduced Risk of Disease Worsening or Death in Patients with Metastatic or Locally Advanced Triple Negative Breast Cancer

Non-Small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)

Celgene Corporation today announced that the Phase III IMpassion130 study, which was sponsored by Roche, met its co-primary endpoint of progression-free survival.